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Barrier dysfunction in allergy
In Allergology International (AI) Vol. 67, Issue 1, we feature a set
of review articles entitled “Barrier dysfunction in allergy” as well as
original articles and letters to the editor. We believe that this issue
will be of great help in understanding how barrier disruptions are
associated with the onset of allergy in barrier organs, which may
lead to the prevention of allergic diseases.
The barrier organsdsuch as the skin, lung, gut, and nasal
cavitydcover the entire body and protect us from the external envi-
ronment. When these barriers are impaired, external toxins pene-
trate the body and induce inﬂammation to defend against them.
Over the last decade, many studies have demonstrated that barrier
dysfunction is a critical component of allergy.1e3 In particular,
inherited defects in epidermal barrier proteins, such as ﬁlaggrin,
facilitate the interaction of external antigens with skin-resident im-
mune cells, driving local inﬂammation that can also lead to systemic
immune responses.4,5 This is the “outside-in” hypothesis of atopic
dermatitis pathogenesis, and it helps to explain why atopic derma-
titis sufferers have an increased risk of developing food allergies,
asthma, and allergic rhinitis later in life, known as the “atopic
(allergic) march”.6 These observations suggest that maintaining
the skin barrier function is important for both effectively managing
atopic dermatitis and preventing subsequent allergic diseases.
In this review article series, Egawa and Kabashima summarize
how the physical barrier of the skin is organized and review its
link to the pathogenesis of skin allergic diseases, such as atopic
dermatitis, from the perspective of the stratum corneum compo-
nents: 1) ﬁlaggrin metabolism, 2) corniﬁed envelope, 3) intercel-
lular lipids, 4) corneodesmosome, and 5) corneocyte
desquamation.7 Gon and Hashimoto summarize the pathogenesis
of bronchial asthma, characterized by the hyper-responsive, chron-
ically inﬂamed airways. Damage to the barrier functions of the
airway epithelium enhances mucosal permeability of foreign sub-
stances, leading to the release of epithelial cytokines (e.g. TSLP,
IL-25, and IL-33), which then activates dendritic cells, Th2 cells,
and type 2 innate lymphoid cells to cause allergic airway inﬂamma-
tion.8 Fukuoka and Yoshimoto summarize the functions of tight
junctions, a cellecell junctional complex located on the apical
side of epithelial cells. And they review an interesting observation
that diesel exhaust particles, the main component of particulate
matter 2.5 (PM2.5), exacerbated allergic rhinitis in a mouse model
through tight junction disruption.9 These ﬁndings suggest that con-
trolling barrier functions is important to prevent allergies, which is
in line with a paradigm shift away from avoidance and delayed
introduction of allergenic foods. Natsume and Ohya show the
increased importance of preventing eczema/atopic dermatitis in in-
fancy.10 Two randomized controlled trials using emollients showed
successful results in preventing infant atopic dermatitis.11,12 Taken
together, recent ﬁndings on barrier dysfunctions in allergy have
revealed the pathogenesis of allergic diseases and pointed the
way to novel strategies to control allergic diseases.13
During the 2015 enterovirus D68 epidemic, both an unusual
cluster of children with acute ﬂaccid paralysis and a high rate of
hospitalization of asthmatic children were observed. Korematsu
et al. report the results of a nationwide retrospective survey con-
ducted by the Japanese Society of Pediatric Allergy and Clinical
Immunology. Their analysis conﬁrms the association between the
unusual increase in acute asthma hospitalizations of children and
the enterovirus D68 epidemic in September 2015 in Japan.14 To
verify a causative role for a respiratory virus in exacerbating asthma
in children, surveillance systems for asthma and respiratory infec-
tious pathogens have been shown to be essential.
The pathogenesis of mild persistent asthma in children, and
optimal treatments for it, remain elusive. Nagao et al. performed
a randomized, controlled trial of treatment of preschool children
with mild persistent asthma using a leukotriene receptor antago-
nist (LTRA), montelukast, daily for 48 weeks [recommended by Jap-
anese Guideline for Childhood Asthma (JGCA)]15 or as-needed b2-
agonist(s) (recommended by GINA and EPR-3 guidelines).16e18
LTRA signiﬁcantly reduced acute exacerbations and the percentage
of children needing step-up treatment. These results not only
demonstrated the superiority of the JGCA guideline, but also sug-
gested the involvement of cysteinyl leukotrienes in the exacerba-
tion and progression of childhood asthma.
Oguma et al. report the ﬁrst nationwide survey of allergic bron-
chopulmonary aspergillosis (ABPA) in Japan, one of the largest
studies examining the clinical characteristics of this disease world-
wide.19 ABPA is an allergic pulmonary disease characterized by a
hypersensitivity reaction to Aspergillus species colonizing the air-
ways. They summarized 358 cases meeting the criteria for possible
ABPA-central bronchiectasis (ABPA-CB) taken from 499 physician-
diagnosed cases reported by 132 clinical centers. This survey iden-
tiﬁed several unique clinical characteristics of ABPA in Japan
compared to other countries: late onset (median: 57 years); rela-
tively lower serum IgE levels, particularly in late-onset patients;
and frequent recurrences/ﬂares (48%). These patients do not meet
the current diagnosis criteria; therefore, somemodiﬁcation of these
criteria is needed for this phenotype of ABPA.
Japanese cedar pollinosis, including allergic rhinitis and
conjunctivitis, has been considered a national afﬂiction in Japan,Peer review under responsibility of Japanese Society of Allergology.
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with a prevalence of >25%.20 Fukuda et al. demonstrated that
feeding mice suffering from allergic conjunctivitis caused by Japa-
nese cedar with transgenic rice expressing two major allergens of
Japanese cedar pollinosis, Cry j 1 and Cry j 2, ameliorated the dis-
ease.21,22 The allergens of Japanese cedar pollinosis are expressed
as fragmented and shufﬂed sequences in the transgenic rice in or-
der to eliminate IgE reactivity, not to cause adverse anaphylactic re-
action. The rice-based edible allergen vaccine for Japanese cedar
pollinosis is potentially effective and safe for oral immunotherapy
in people suffering from this condition.
We offer our appreciation to all the authors for their contribu-
tions to the present issue of Allergology International.
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